financetom
Business
financetom
/
Business
/
PhonePe launches platform for merchant lending in boost for SME loans
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PhonePe launches platform for merchant lending in boost for SME loans
Jun 23, 2023 10:11 AM

PhonePe, one of India's largest fintech platforms, on Friday (June 23), said it has launched its merchant lending platform, allowing banks and NBFCs to provide access to credit in a completely digital and seamless manner to its vast base of over 35 million merchants.

Share Market Live

NSE

SMEs (small and medium enterprises) in India have long faced challenges in accessing organised credit, impeding their growth, the company said.

Understanding this unmet need, PhonePe has designed a seamless end-to-end journey on the PhonePe for Business app, ensuring that loans are approved by lending partners in a matter of minutes.

Also Read: Byju's may face a government probe, company says it hasn't got any notice so far

PhonePe leverages its strong distribution network and superior tech capabilities, while the lending partners bring in their expertise in underwriting, disbursals, and loan collection. The company has successfully facilitated the disbursal of over 20,000 loans through its trusted NBFC partners since May 2023.

Hemant Gala, Vice President of Financial Services, said, "Promoting financial inclusion is at the core of PhonePe’s mission. We are excited to launch merchant lending on our platform using the marketplace model, providing SMEs & MSMEs with access to organised credit and enabling their growth."

Also Read: Orchid Pharma launches QIP to raise funds - Floor price fixed at Rs 425

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate
Mesoblast Files Meeting Request With FDA for Ischemic Heart Failure Treatment Candidate
Apr 3, 2025
04:23 AM EDT, 04/03/2025 (MT Newswires) -- Mesoblast (MESO) said late Wednesday it expets to have a type B meeting with the US Food and Drug Administration during the current quarter to discuss the accelerated approval pathway for ischemic heart failure treatment candidate, Revascor. The main goals of the meeting are to get FDA feedback on relevant chemistry, manufacturing &...
Traders seek refuge in Aussie consumer staples as US tariffs spark market fall
Traders seek refuge in Aussie consumer staples as US tariffs spark market fall
Apr 3, 2025
By Rajasik Mukherjee (Reuters) - Shares of Australia's consumer staple companies rose on Thursday, driven by grocers Coles and Woolworths, as investors moved to safer bets after U.S. President Donald Trump's reciprocal tariffs sparked global market turmoil. Shares of the sector ended 1.3% higher while the broader Australian market fell 0.9% to its lowest since March 14. Coles rose 2.1%...
Trump's Tariffs Announcement 'Worse Than the Worst Case Scenario,' Wedbush Says
Trump's Tariffs Announcement 'Worse Than the Worst Case Scenario,' Wedbush Says
Apr 3, 2025
04:35 AM EDT, 04/03/2025 (MT Newswires) -- The slate of tariffs from the Trump administration is worse than the worst case scenario feared by analysts, according to Wedbush Securities. In a note emailed to clients on Wednesday, Wedbush analysts, led by Daniel Ives, said tech stocks will be under major pressure following the announcement. On Wednesday, the Trump administration unveiled...
Novartis Gets FDA Accelerated Approval for Vanrafia
Novartis Gets FDA Accelerated Approval for Vanrafia
Apr 3, 2025
04:41 AM EDT, 04/03/2025 (MT Newswires) -- Novartis ( NVS ) said late Wednesday the US Food and Drug Administration granted accelerated approval for Vanrafia to reduce proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression. IgAN is a progressive, rare kidney disease. Data from an ongoing phase III showed that Vanrafia achieved...
Copyright 2023-2025 - www.financetom.com All Rights Reserved